The acting director of the National Institute of Allergy and Infectious Diseases (NIAID) has stepped down, leaving yet another leadership vacancy at the National Institutes of Health (NIH) — and federal health officials are refusing to explain why. Story Snapshot Jeffery Taubenberger stepped down as acting director of NIAID, confirmed during a Senate Appropriations Committee hearing by Sen. Tammy Baldwin. The Department of Health and Human Services (HHS) has not responded to press inquiries, and NIAID staff were reportedly not informed of the change. Taubenberger had served as acting director since April 2025, replacing Jeanne Marrazzo, who was placed on administrative leave under the Trump administration. The exact timing and reason for Taubenberger’s departure remain publicly unknown, fueling speculation about the circumstances surrounding his exit. Another NIAID Leadership Vacancy Surfaces Sen. Tammy Baldwin disclosed during a Senate Appropriations Committee hearing that Jeffery Taubenberger had stepped down as acting head of NIAID, one of the federal government’s largest and most influential health research institutes. STAT News reported the development on May 21, 2026, noting that the agency’s leadership status had become “unclear” and that queries to HHS “have gone unanswered and unacknowledged.” NIAID staff, according to the report, had not been formally informed of the change. Taubenberger was appointed acting director of NIAID in April 2025, stepping into the role after Jeanne Marrazzo was placed on administrative leave as part of the Trump administration’s broader restructuring of federal health agencies. NIH Director Jay Bhattacharya publicly acknowledged Taubenberger in the position through an NIH video, describing him as acting director of the National Institute of Allergy and Infectious Diseases. His tenure in that role ran approximately from April 2025 through May 2026. Silence From HHS Raises Questions What stands out most is not the departure itself but the institutional silence surrounding it. Large federal agencies routinely cycle through acting leadership during transitions, and that alone would not be newsworthy. What makes this different is that HHS failed to respond to press inquiries, NIAID employees were left uninformed, and the disclosure came not from the agency but from a senator during a budget hearing. That combination of opacity is not consistent with a routine administrative handoff. The exact date Taubenberger stepped down has not been publicly established. STAT reported it was “unclear when Taubenberger stepped down, or why,” and noted that internal chatter within the institute had been circulating before the public disclosure. Whether the departure was voluntary, requested by NIH leadership, or the result of a broader personnel decision remains undocumented in any public record. HHS has offered no clarifying statement as of the time of reporting. Gain-of-Function Controversy Shadows the Exit Taubenberger is a virologist known for his work reconstructing the 1918 influenza pandemic virus — research that has drawn scrutiny from critics of high-risk pathogen studies. Conservative activist group White Coat Waste Project had publicly targeted him in connection with gain-of-function research concerns, and his association with the broader NIH scientific establishment made him a figure of interest to those pushing for accountability in federal pandemic research programs. Those criticisms formed the backdrop against which his departure became public. 1/ It was revealed today that the acting head of NIAID that replaced Fauci, Jeffrey Taubenberger, has stepped down. There is yet no current information available publicly as to why. Here is a reminder on who Jeffrey is and why having that position was a threat to humans… https://t.co/bRUPCtwjPz — Melissa (@missyTHX1138) May 21, 2026 However, the available public record does not establish a direct causal link between activist pressure and Taubenberger’s exit. No resignation letter, internal memo, personnel action notice, or on-record statement from NIH or HHS connects his departure to gain-of-function research criticism or any specific campaign. The facts on record are that he held the role, he no longer holds it, and the government has not explained the change. That gap between what is known and what is being claimed is significant — and it is a gap the administration should close with a straightforward public statement. NIH Accountability Demands Transparency American taxpayers fund the NIH to the tune of tens of billions of dollars annually. The public has a legitimate interest in knowing who is running its largest infectious disease research institute and why leadership changes occur. The Trump administration has made NIH reform a stated priority, which makes the silence around this departure harder to justify — not easier. Accountability cannot be a one-way street that applies only to the previous administration’s decisions. When federal health agencies go dark on basic personnel questions, they undermine the very trust conservatives have demanded be restored to American public health institutions. Sources: [1] Web – Acting head of NIH’s infectious disease institute reported to have … [2] Web – Jeffery Taubenberger Named Acting Director of NIAID – AABB.org [3] YouTube – Dr. Jeffery Taubenberger & NIAID – Director’s Desk [4] Web – Jeffery Taubenberger – Wikipedia